SQI Diagnostics Inc. (SQIDF) Research

SQI Diagnostics Inc. operates as a precision medicine firm, engaged in the global identification, advancement, and marketing of swift diagnostic solutions tailored for medical professionals, patients, and the general public. Its diverse product portfolio features TOR-dx, a specialized lung test designed to help surgeons evaluate the condition of donor lungs. The company also offers an at-home antibody test kit for COVID-19, along with RALI-Dx, a laboratory-based test for triaging COVID-19 severity, and RALI-fast, its rapid point-of-care alternative for the same purpose. Furthermore, SQI Diagnostics provides essential microarray instruments to support antibody testing procedures. The company was founded in 1999 and maintains its corporate headquarters in Toronto, Canada.

Market snapshot

Symbol
SQIDF
Price
$0.01
Day change
+14.62%
Market cap
$8.6M
P/E ratio
-0.44x
52-week range
0.013-0.015
Sector
Healthcare
Industry
Medical - Diagnostics & Research

Peer companies

  • The BC Bud Corporation (BCBCF)
  • Bloom Health Partners Inc. (BLMHF)
  • CLS Holdings USA, Inc. (CLSH)
  • CloudMD Software & Services Inc. (DOCRF)
  • Deltex Medical Group plc (DTXMF)
  • Fire & Flower Holdings Corp. (FFLWF)
  • MDxHealth S.A. (MXDHF)
  • Polydex Pharmaceuticals Limited (POLXF)

Open SQI Diagnostics Inc. (SQIDF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.